|
ES8502612A1
(es)
|
1983-06-15 |
1985-02-01 |
Schering Ag |
Procedimiento para la preparacion de 13a-alquilgonanos
|
|
DE3321826A1
(de)
|
1983-06-15 |
1984-12-20 |
Schering AG, 1000 Berlin und 4709 Bergkamen |
13(alpha)-alkylgonane, deren herstellung und diese enthaltende pharmazeutische praeparate
|
|
US4780461A
(en)
|
1983-06-15 |
1988-10-25 |
Schering Aktiengesellschaft |
13α-alkyl-gonanes, their production, and pharmaceutical preparations containing same
|
|
US4742000A
(en)
|
1986-05-02 |
1988-05-03 |
University Of Chicago |
Antibody to human progesterone receptor and diagnostic materials and methods
|
|
DE3630030A1
(de)
|
1986-09-01 |
1988-03-03 |
Schering Ag |
13(alpha)-alkylgonan-(delta)(pfeil hoch)9(pfeil hoch)(pfeil hoch)((pfeil hoch)(pfeil hoch)1(pfeil hoch)1(pfeil hoch))(pfeil hoch)-5,10-epoxide
|
|
US4774236A
(en)
|
1986-09-17 |
1988-09-27 |
Research Triangle Institute |
17α-(substituted-methyl)-17β-hydroxy/esterified hydroxy steroids and pharmaceutical compositions containing them
|
|
IE60780B1
(en)
|
1987-01-23 |
1994-08-10 |
Akzo Nv |
New 11-aryl steroid derivatives
|
|
DE3822770A1
(de)
|
1988-07-01 |
1990-01-04 |
Schering Ag |
13-alkyl-11ss-phenylgonane
|
|
US5283190A
(en)
|
1989-07-31 |
1994-02-01 |
Traish Adbulmaged M |
Specific monoclonal antibodies against a defined epitope of progesterone receptor and methods for their use
|
|
DE4008584A1
(de)
|
1990-03-15 |
1991-09-26 |
Schering Ag |
Verfahren zur herstellung von zwischenprodukten fuer die antigestagensynthese (onapristonsynthese)
|
|
US5141961A
(en)
|
1991-06-27 |
1992-08-25 |
Richrdson-Vicks Inc. |
Process for solubilizing difficulty soluble pharmaceutical actives
|
|
MX9301121A
(es)
|
1992-03-02 |
1993-09-01 |
Schering Ag |
Metodo y equipo para la contracepcion oral y regulacion de la menstruacion con estrogeno/progestina/aniprogestina.
|
|
CN1053450C
(zh)
|
1992-11-19 |
2000-06-14 |
北京第三制药厂 |
17位取代11β－取代芳香基－4,9－雌甾二烯类化合物的全合成法
|
|
DE4332283A1
(de)
|
1993-09-20 |
1995-04-13 |
Jenapharm Gmbh |
Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
|
|
JPH10507461A
(ja)
*
|
1994-10-24 |
1998-07-21 |
シエーリング アクチエンゲゼルシヤフト |
必要に応じて女性の稔性を調節するための競合的プロゲステロン拮抗物質
|
|
US5759577A
(en)
|
1995-01-17 |
1998-06-02 |
American Home Products Corporation |
Controlled release of steroids from sugar coatings
|
|
US6900193B1
(en)
|
1996-05-01 |
2005-05-31 |
The United States Of America As Represented By The Department Of Health And Human Services |
Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents
|
|
IL122740A
(en)
|
1997-01-15 |
2003-09-17 |
Akzo Nobel Nv |
16-hydroxy-11-(substituted phenyl)-estra-9,4-diene derivatives, their preparation and pharmaceutical compositions containing them
|
|
US5962444A
(en)
|
1998-05-29 |
1999-10-05 |
Research Triangle Institute |
17β-nitro-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
|
|
US6537584B1
(en)
|
1999-11-12 |
2003-03-25 |
Macromed, Inc. |
Polymer blends that swell in an acidic environment and deswell in a basic environment
|
|
WO2001089566A1
(en)
|
2000-05-19 |
2001-11-29 |
Genentech, Inc. |
Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy
|
|
US6750015B2
(en)
|
2000-06-28 |
2004-06-15 |
Kathryn B. Horwitz |
Progesterone receptor-regulated gene expression and methods related thereto
|
|
UY26966A1
(es)
|
2000-10-18 |
2002-06-20 |
Schering Ag |
Uso de antiprogestinas para la inducción de apoptosis en una célula
|
|
US7381976B2
(en)
|
2001-03-13 |
2008-06-03 |
Triton Thalassic Technologies, Inc. |
Monochromatic fluid treatment systems
|
|
AUPR546801A0
(en)
|
2001-06-05 |
2001-06-28 |
Commonwealth Scientific And Industrial Research Organisation |
Recombinant antibodies
|
|
US7105642B2
(en)
|
2001-08-03 |
2006-09-12 |
Cell Signalling Technology, Inc. |
Monoclonal antibodies specific for phosphorylated estrogen receptor alpha (Ser118) and uses thereof
|
|
US20040121304A1
(en)
|
2001-12-21 |
2004-06-24 |
Ulrike Fuhrmann |
Method for screening for progesterone receptor isoform-specific ligands and for tissue-selective progesterone receptor ligands
|
|
JP2006519255A
(ja)
|
2003-02-28 |
2006-08-24 |
アメリカ合衆国 |
１７α−アセトキシ−１１β−（４−Ｎ，Ｎ−ジメチルアミノフェニル）−１９−ノルプレグナ−４，９−ジエン−３，２０−ジオンの製造方法、その中間体及びそのような中間体の製造方法
|
|
US20040265371A1
(en)
|
2003-06-25 |
2004-12-30 |
Looney Dwayne Lee |
Hemostatic devices and methods of making same
|
|
US7247625B2
(en)
*
|
2003-10-09 |
2007-07-24 |
Wyeth |
6-amino-1,4-dihydro-benzo[d][1,3] oxazin-2-ones and analogs useful as progesterone receptor modulators
|
|
ES2360806T3
(es)
|
2004-07-09 |
2011-06-09 |
The Population Council, Inc. |
Composiciones de liberación prolongada que contienen moduladores de receptores de progesterona.
|
|
WO2006036726A1
(en)
|
2004-09-22 |
2006-04-06 |
Tripath Imaging, Inc. |
Methods and computer program products for analysis and optimization of marker candidates for cancer prognosis
|
|
CA2604218A1
(en)
|
2005-04-20 |
2006-10-26 |
Pfizer Limited |
Pyrazole derivatives as progesterone receptor antagonists
|
|
EP2021499A4
(en)
|
2005-12-16 |
2010-02-17 |
Univ Leland Stanford Junior |
FUNCTIONAL ARRAYS FOR THE IDENTIFICATION OF ELEMENTS FOR GENE PRESSION REGULATION WITH HIGH THROUGHPUT
|
|
US20070167971A1
(en)
|
2006-01-17 |
2007-07-19 |
Raymond Huey |
Devices and methods for promoting the formation of blood clots in esophageal varices
|
|
US20070166372A1
(en)
|
2006-01-19 |
2007-07-19 |
Mai De Ltd. |
Preparation of solid coprecipitates of amorphous valsartan
|
|
WO2007098381A2
(en)
|
2006-02-17 |
2007-08-30 |
Janssen Pharmaceutica N.V. |
11-phosphorous steroid derivatives useful as progesterone receptor modulators
|
|
DE102006054535A1
(de)
|
2006-11-15 |
2008-05-21 |
Bayer Schering Pharma Aktiengesellschaft |
Progesteronrezeptorantagonisten
|
|
WO2008128783A2
(en)
|
2007-04-24 |
2008-10-30 |
Dsm Ip Assets B.V. |
Photochemical process for the preparation of a previtamin d
|
|
CA2596204C
(en)
|
2007-08-07 |
2019-02-26 |
Historx, Inc. |
Method and system for determining an optimal dilution of a reagent
|
|
WO2009025759A1
(en)
|
2007-08-17 |
2009-02-26 |
Progenics Pharmaceuticals (Nevada), Inc. |
Tight junction proteins associated with infection and entry of hepatitis c virus (hcv), methods and uses thereof
|
|
EP2209493A2
(en)
*
|
2007-10-12 |
2010-07-28 |
Novartis AG |
Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators
|
|
EP2075246A1
(en)
|
2007-12-27 |
2009-07-01 |
M. J. Institute of Research |
A process for preparation of amorphous form of atorvastatin hemi-calcium salt
|
|
EA018974B9
(ru)
|
2008-02-05 |
2014-04-30 |
Харбор Терапьютикс, Инк. |
Твердые лекарственные формы
|
|
TW201002736A
(en)
|
2008-04-28 |
2010-01-16 |
Repros Therapeutics Inc |
Compositions and methods for treating progesterone-dependent conditions
|
|
TWI539953B
(zh)
|
2008-04-28 |
2016-07-01 |
瑞波若斯治療學公司 |
用於治療乳癌之組成物和方法
|
|
US8744695B2
(en)
|
2009-03-27 |
2014-06-03 |
Komatsu Ltd. |
Fuel consumption saving control device for work vehicle and fuel consumption saving method for work vehicle
|
|
US9074002B2
(en)
|
2009-04-27 |
2015-07-07 |
Cold Spring Harbor Laboratory |
PTP1B inhibitors
|
|
US20110003753A1
(en)
|
2009-06-01 |
2011-01-06 |
Samuel Waxman Cancer Research Foundation |
COMPOSITIONS AND METHODS FOR DISRUPTING THE FUNCTION OF THE TRANSCRIPTIONAL REPRESSOR COMPONENT Sin3A-PAH2 DOMAIN TO INDUCE DIFFERENTIATION AND GROWTH INHIBITION IN BREAST CANCER
|
|
JP6013911B2
(ja)
|
2009-07-15 |
2016-10-25 |
シーティーアイ・バイオファーマ・コーポレーションＣＴＩ ＢｉｏＰｈａｒｍａ Ｃｏｒｐ． |
９ｅ−１５−（２−ピロリジン−１−イル−エトキシ）−７，１２，２５−トリオキサ−１９，２１，２４−トリアザ−テトラシクロ［１８．３．１．１（２，５）．１（１４，１８）］ヘキサコサ−１（２４），２，４，９，１４，１６，１８（２６），２０，２２−ノナエンのクエン酸塩
|
|
US20110293511A1
(en)
|
2009-09-29 |
2011-12-01 |
Terrance Grant Johns |
Specific binding proteins and uses thereof
|
|
US8261855B2
(en)
*
|
2009-11-11 |
2012-09-11 |
Flanders Electric, Ltd. |
Methods and systems for drilling boreholes
|
|
US9295649B2
(en)
|
2009-12-15 |
2016-03-29 |
Bind Therapeutics, Inc. |
Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers
|
|
EP2550288A1
(en)
*
|
2010-03-22 |
2013-01-30 |
Repros Therapeutics Inc. |
Compositions and methods for non-toxic delivery of antiprogestins
|
|
DK2638163T3
(en)
|
2010-11-12 |
2017-07-24 |
Massachusetts Gen Hospital |
POLYCOMB-ASSOCIATED NON-CODING RNAs
|
|
EP2651400B2
(en)
|
2010-12-16 |
2023-01-18 |
Amgen (Europe) GmbH |
Controlled release oral dosage forms of poorly soluble drugs and uses thereof
|
|
DK2655621T3
(en)
|
2010-12-20 |
2018-08-13 |
Massachusetts Gen Hospital |
Polycomb-associated non-coding RNAS
|
|
WO2012122514A1
(en)
|
2011-03-09 |
2012-09-13 |
Centrose, Llc |
Extracellular targeted drug conjugates
|
|
PL2683384T3
(pl)
*
|
2011-03-11 |
2016-06-30 |
Celgene Corp |
Sposoby leczenia nowotworu z użyciem 3-(5-amino-2-metylo-4-okso-4h-chinazolin-3-ylo)piperydyno-2,6-dionu
|
|
US9618512B2
(en)
|
2011-04-15 |
2017-04-11 |
J-Pharma Co., Ltd. |
Biomarker for breast cancer
|
|
NZ706004A
(en)
|
2011-05-13 |
2016-12-23 |
Ganymed Pharmaceuticals Ag |
Antibodies for treatment of cancer expressing claudin 6
|
|
US20130029953A1
(en)
|
2011-07-28 |
2013-01-31 |
Klaus Nickisch |
Progesterone antagonists
|
|
PH12014500683A1
(en)
|
2011-10-04 |
2014-05-12 |
Invivis Pharmaceuticals Inc |
Methods and systems for identfying and treating anti-progestin sensitive tumors
|
|
US10039806B2
(en)
|
2011-12-08 |
2018-08-07 |
Fundacion Sales |
Methods and compositions for treating antiprogestin-resistant cancers
|
|
US20130338016A1
(en)
|
2012-04-17 |
2013-12-19 |
Vala Sciences, Inc. |
Method For Integrated Pathology Diagnosis And Digital Biomarker Pattern Analysis
|
|
EP2841594A1
(en)
|
2012-04-27 |
2015-03-04 |
Regents of the University of Minnesota |
Breast cancer prognosis, prediction of progesterone receptor subtype and!prediction of response to antiprogestin treatment based on gene expression
|
|
AU2013295815A1
(en)
|
2012-07-24 |
2015-02-05 |
Cedars-Sinai Medical Center |
A novel method to detect resistance to chemotherapy in patients with lung cancer
|
|
AU2013358968B2
(en)
|
2012-12-13 |
2017-12-21 |
Warsaw Orthopedic, Inc. |
Compositions and methods comprising polyethylene glycol and magnesium for treatment of neuronal injury
|
|
CA2904116C
(en)
*
|
2013-03-12 |
2021-09-14 |
Arno Therapeutics |
Onapristone polymorphic forms and methods of use
|
|
US20140363425A1
(en)
|
2013-03-13 |
2014-12-11 |
J. Dinny Graham |
Systems and methods for identifying cancers having activated progesterone receptors
|
|
US9096641B2
(en)
|
2013-06-05 |
2015-08-04 |
Evestra, Inc. |
Imidazolyl progesterone antagonists
|
|
CN103483449A
(zh)
|
2013-08-20 |
2014-01-01 |
东北农业大学 |
两种scFv抗体、其编码基因及其在制备治疗或预防鸡传染性法氏囊病制剂中的应用
|
|
AU2015243969A1
(en)
|
2014-04-08 |
2016-09-01 |
Context Biopharma Inc. |
Systems and methods for identifying progesterone receptor subtypes
|
|
CA2966753A1
(en)
|
2014-11-17 |
2016-05-26 |
Arno Therapeutics, Inc. |
Onapristone extended-release compositions and methods
|
|
WO2016154203A1
(en)
|
2015-03-23 |
2016-09-29 |
Evestra, Inc. |
Novel cytotoxic agents that preferentially target leukemia inhibitory factor (lif) for the treatment of malignancies and as new contraceptive agents
|
|
AU2016326657B2
(en)
|
2015-09-25 |
2019-10-24 |
Context Biopharma, Inc. |
Methods of making onapristone intermediates
|
|
JP2019503353A
(ja)
|
2015-12-15 |
2019-02-07 |
コンテキスト・バイオファーマ・インコーポレイテッド |
非晶質オナプリストン組成物およびそれを作製する方法
|
|
JP2019513706A
(ja)
|
2016-03-21 |
2019-05-30 |
コンテキスト・バイオファーマ・インコーポレイテッド |
オナプリストン代謝物質組成物及び方法
|
|
CA3022961A1
(en)
|
2016-05-02 |
2017-11-09 |
Tetragenetics, Inc. |
Anti-kv1.3 antibodies, and methods of production and use thereof
|
|
WO2018067198A1
(en)
|
2016-10-03 |
2018-04-12 |
The Regents Of The University Of California |
Inhibitory antibodies and methods of use thereof
|